Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) reported today its operational and financial results for the three and ...

Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE ...

MIGDAL HAEMEK, Israel, Nov. 10, 2025 /PRNewswire/ -- Camtek Ltd. (NASDAQ: CAMT) (TASE: CAMT), today announced its financial ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Detailed price information for Pubmatic Inc Cl A (PUBM-Q) from The Globe and Mail including charting and trades.

SLC35G3-mediated UDP-GlcNAc transport is essential for proper sperm glycoprotein formation and male fertility.

Since September 30, 2025 the company has purchased 107,525 of its subordinate voting shares for cancellation at an aggregate cost of $178.4 million or $1,659.19 per share.

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...